Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer. 2021

Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
Department of Pathology, Hitit University Faculty of Medicine, Çorum Turkey. Electronic address: yilbas@yahoo.com.

We investigated programmed cell death 1 (PD-1) / programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer (HGSOC) and its relationship to tumor infiltrating lymphocytes (TIL) and prognosis. Formalin fixed paraffin embedded (FFPE) samples of 94 HGSOC cases were included in the study. Immunohistochemical analysis (CD3, CD4, CD8, PD-1 and PD-L1) was performed. Samples were analyzed for expression of immune proteins in the peritumoral stromal and intratumoral areas, scored, and expression was correlated with overall survival, stage, and age. PD-L1 staining ratio with a score greater than 0 was found to have lower survival. There were two positive staining patterns, patchy/diffuse and patchy/focal patterns, in 24 (25.5%) cases. Considering the threshold value ≥5%, we demonstrated that the PD-L1 positive cancer cell membrane immunoreactivity rate and patchy/diffuse PD-L1 expression were 9.6% (n = 9). There was statistically significant relationship between high PD-1 scores and PD-L1 cases of ≥ 5%. A statistically significant difference was found between PD-L1 staining and survival in patients with a threshold ≥ 5%. However an appropriate rate for treatment was determined in 9.6% cases. There was a statistically significant correlation between PD-1 positive TIL score and intratumoral CD3, peritumoral stromal CD3, intratumoral CD4 and intratumoral CD8 positive cells. Survival was lower in cases with higher PD-L1 positive stromal TIL score.

UI MeSH Term Description Entries

Related Publications

Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
January 2016, Oncotarget,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
July 2018, American journal of clinical oncology,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
April 2016, Molecular diagnosis & therapy,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
January 2020, European journal of obstetrics, gynecology, and reproductive biology,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
May 2018, Journal of ovarian research,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
June 2021, Breast cancer research and treatment,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
October 2023, Diagnostics (Basel, Switzerland),
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
January 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
November 2017, Journal of gynecologic oncology,
Yılmaz Baş, and Nermin Koç, and Kaan Helvacı, and Cem Koçak, and Raşit Akdeniz, and Havva Hande Keser Şahin
August 2015, Zhongguo shi yan xue ye xue za zhi,
Copied contents to your clipboard!